Improving Negative Symptoms & Community Engagement in Veterans With Schizophrenia
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The goal of this study is to evaluate an innovative psychosocial intervention package that will incorporate evidence-based treatment strategies to target the affective-motivational deficits, negative expectancies, and behavioral skills deficits that are central to the maintenance of negative symptoms. The intervention - called EnCoRE (Engaging in Community Roles and Experiences) - will include strategies aimed at teaching Veterans with schizophrenia and negative symptoms ways to (1) overcome deficits in anticipatory pleasure, (2) increase intrinsic motivation for goal-directed activities, (3) reduce expectancies for failure, and (4) perform skillfully in new social situations, all of which can impact implementation of new skills and behaviors. Rather than develop a new set of intervention strategies, the investigators will include within EnCoRE evidence-based strategies for these treatment domains. In addition, the investigators will collect qualitative information both from Veterans concerning their perceptions of the strengths, weaknesses, and barriers to participation in EnCoRE, as well as from a sample of mental health providers who work with Veterans with schizophrenia and negative symptoms, in order to inform a larger scale implementation trial should EnCoRE prove effective here.
Following a short pilot to train interventionists and refine the manual, the investigators will conduct a randomized controlled trial to test the efficacy of EnCoRE in improving ratings of negative symptoms, functional outcomes, and engagement in community activities in a sample of Veterans with schizophrenia and negative symptoms (n=108). Participants will be randomized either to EnCoRE or a health-related control group. These goals fit well within the objectives of the Rehabilitation Research and Development (RR&D) program of funding research aimed at studying rehabilitation interventions focused on maximizing functional recovery and assisting in the integration of Veterans into civilian life. Specifically, the investigators will address the following Specific Aims:
Specific Aim 1: Train therapists and refine the EnCoRE manual in a preliminary trial with 10 Veterans with schizophrenia and negative symptoms.
Specific Aim 2: Conduct a randomized controlled trial (n=108, medium effect, alpha=.05) to test the efficacy of EnCoRE in producing positive changes at post-treatment and 3-month follow-up on the primary outcomes of negative symptoms and social and community functioning.
Specific Aim 3: Examine qualitative interviews completed by (1) Veterans who participated in EnCoRE and (2) Mental Health Providers to determine aspects of EnCoRE that were perceived as more or less helpful, interesting, and valuable in order to make adjustments prior to conducting a larger, multi-site implementation trial.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21201
- Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Diagnostic and Statistical Manual of Disorders, 5th edition (DSM 5) diagnosis of schizophrenia or schizoaffective disorder
A minimum average rating of a "moderately severe deficit" (3 or greater on a 0-4 scale) on one symptom domain or a minimum average rating of a "moderate deficit" (2 or greater on a 0-4 scale) on two or more domains, within the affect motivation factor of the Clinical Assessment Interview for Negative Symptoms (CAINS) i.e.,:
- symptoms of asociality
- avolition
- anhedonia
- Age between 18 and 75 years
- Seen by a service provider twice within the last 6 months or once in the last 6 months consistently for two years, as in line with the Veteran's recorded mental health treatment plan (to demonstrate that participants receive ongoing and regular mental health care)
- Competent to sign Informed Consent
Exclusion Criteria:
- Documented history of serious neurological disorder or head trauma with loss of consciousness
- Cognitive impairment (defined as a total intelligence quotient (IQ) score less than 70 as measured by the Wechsler Test of Adult Reading or as indicated by chart review
- Inability to effectively participate in the baseline assessments due to psychiatric symptoms on two successive appointments
- Current problematic substance use as indexed by scores on the Michigan Alcoholism Screening Test and the Drug Abuse Screening Test
- Currently meet criteria for a major depressive episode
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Engaging in Community Roles and Experiences (ENCoRE)
Engaging in Community Roles and Experiences (ENCoRE) includes evidence-based psychosocial treatment strategies to target the affective-motivational deficits, negative expectancies, and behavioral skills deficits that are central to the maintenance of negative symptoms.
Behavioral strategies include motivational enhancement, psychoeducation, cognitive therapy, and social skills training.
|
Engaging in Community Roles and Experiences (ENCoRE) includes evidence-based psychosocial treatment strategies to target the affective-motivational deficits, negative expectancies, and behavioral skills deficits that are central to the maintenance of negative symptoms.
Behavioral strategies include motivational enhancement, psychoeducation, cognitive therapy, and social skills training.
Otros nombres:
|
|
Comparador activo: Health & Wellness (H&W)
Health & Wellness (H&W) will focus on health and wellness issues and education on ways to better manage health-related concerns following a basic structure that includes: review of the previous session's material, new educational content, and discussion/application.
Topics will include: 1) Overview, 2) Physical Activity (3 sessions), 3) Nutrition/Healthy Eating (3 sessions), 4) Managing Fatigue/Sleep (3 sessions), 5) Relaxation (3 sessions), 6) Tobacco cessation (3 sessions), 7) Substance Use (3 sessions), 8) Medication/Side Effects (3 sessions), 9) Review (1 session), and Closing (1session).
|
Health & Wellness (H&W) will focus on health and wellness issues and education on ways to better manage health-related concerns following a basic structure that includes: review of the previous session's material, new educational content, and discussion/application. Topics will include: 1) Overview, 2) Physical Activity (3 sessions), 3) Nutrition/Healthy Eating (3 sessions), 4) Managing Fatigue/Sleep (3 sessions), 5) Relaxation (3 sessions), 6) Tobacco cessation (3 sessions), 7) Substance Use (3 sessions), 8) Medication/Side Effects (3 sessions), 9) Review (1 session), and Closing (1session).
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Clinical Assessment Interview for Negative Symptoms Motivation & Pleasure Scale (CAINS MAP) - 12 Weeks
Periodo de tiempo: Participants will be assessed following completion of the study intervention, an expected average of 12 weeks
|
Differences in mean change on the CAINS MAP scale from baseline assessment to 12 week assessment.
This scale contains a total of 9 items, each with a range of 0-4.
Scores range from 0-36.
Lower scores mean a better outcome.
|
Participants will be assessed following completion of the study intervention, an expected average of 12 weeks
|
|
Social Functioning Scale (SFS) - 12 Weeks
Periodo de tiempo: Participants will be assessed following completion of the study intervention, an expected average of 12 weeks
|
Differences in mean change on the SFS from baseline assessment to 12 week assessment.
In the present analysis, we used a total score for the SFS including all subscales except the employment subscale.
Scores ranged from 13-213.
Higher scores mean a better outcome.
|
Participants will be assessed following completion of the study intervention, an expected average of 12 weeks
|
|
Clinical Assessment Interview for Negative Symptoms Motivation & Pleasure Scale (CAINS MAP) - 24 Weeks
Periodo de tiempo: Participants will be assessed a second time following completion of the study intervention, an expected average of 24 weeks
|
Differences in mean change on the CAINS MAP scale from baseline assessment to 24 week assessment.
This scale contains a total of 9 items, each with a range of 0-4.
Scores range from 0-36.
Lower scores mean a better outcome.
|
Participants will be assessed a second time following completion of the study intervention, an expected average of 24 weeks
|
|
Social Functioning Scale (SFS) - 24 Weeks
Periodo de tiempo: Participants will be assessed a second time following completion of the study intervention, an expected average of 24 weeks
|
Differences in mean change on the SFS from baseline assessment to 24 week assessment.
In the present analysis, we used a total score for the SFS including all subscales except the employment subscale.
Scores ranged from 13-213.
Higher scores mean a better outcome.
|
Participants will be assessed a second time following completion of the study intervention, an expected average of 24 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
University of California San Diego Performance Based Skills Assessment - Brief (UPSA-B) - 12 Weeks
Periodo de tiempo: Participants will be assessed following completion of the study intervention, an expected average of 12 weeks
|
Differences in mean change on the UPSA-B from baseline assessment to 12 week assessment.
The UPSA-B has a range of 0-100 with higher scores mean a better outcome.
In the present analysis, we used the square root of UPSA-B scores with range 0-10.
|
Participants will be assessed following completion of the study intervention, an expected average of 12 weeks
|
|
Maryland Assessment of Recovery Scale (MARS) - 12 Weeks
Periodo de tiempo: Participants will be assessed following completion of the study intervention, an expected average of 12 weeks
|
Differences in mean change on the MARS from baseline assessment to 12 week assessment.
Scores can range from 25-125.
Higher scores mean a better outcome.
|
Participants will be assessed following completion of the study intervention, an expected average of 12 weeks
|
|
Clinical Assessment Interview for Negative Symptoms Social Motivation and Pleasure Subscale (CAINS SMAP) - 12 Weeks
Periodo de tiempo: Participants will be assessed following completion of the study intervention, an expected average of 12 weeks
|
Differences in mean change on the CAINS SMAP from baseline assessment to 12 week assessment.
This subscale has a total of 4 items each rated on a 0-4 score.
The range of scores was 0-16.
Lower scores mean a better outcome.
|
Participants will be assessed following completion of the study intervention, an expected average of 12 weeks
|
|
Role Functioning Scale (RFS) - 12 Weeks
Periodo de tiempo: Participants will be assessed following completion of the study intervention, an expected average of 12 weeks
|
Differences in mean change on the RFS from baseline assessment to 12 week assessment.
Items are rated on a 1 to 7 scale.
In the present analysis, we summed ratings of Family Network Relationships and Immediate Social Network Relationships as our measure of role functioning.
Scores can range from 2-14.
Higher scores mean a better outcome.
|
Participants will be assessed following completion of the study intervention, an expected average of 12 weeks
|
|
University of California San Diego Performance Based Skills Assessment - Brief (UPSA-B) - 24 Weeks
Periodo de tiempo: Participants will be assessed following completion of the study intervention, an expected average of 24 weeks
|
Differences in mean change on the UPSA-B from baseline assessment to 24 week assessment.
The UPSA-B has a range of 0-100 with higher scores mean a better outcome.
In the present analysis, we used the square root of UPSA-B scores with range 0-10.
|
Participants will be assessed following completion of the study intervention, an expected average of 24 weeks
|
|
Maryland Assessment of Recovery Scale (MARS) - 24 Weeks
Periodo de tiempo: Participants will be assessed following completion of the study intervention, an expected average of 24 weeks
|
Differences in mean change on the MARS from baseline assessment to 24 week assessment.
Scores can range from 25-125.
Higher scores mean a better outcome.
|
Participants will be assessed following completion of the study intervention, an expected average of 24 weeks
|
|
Clinical Assessment Interview for Negative Symptoms Social Motivation and Pleasure Subscale (CAINS SMAP) - 24 Weeks
Periodo de tiempo: Participants will be assessed following completion of the study intervention, an expected average of 24 weeks
|
Differences in mean change on the CAINS SMAP from baseline assessment to 24 week assessment.
This subscale has a total of 4 items each rated on a 0-4 score.
The range of scores was 0-16.
Lower scores mean a better outcome.
|
Participants will be assessed following completion of the study intervention, an expected average of 24 weeks
|
|
Role Functioning Scale (RFS) - 24 Weeks
Periodo de tiempo: Participants will be assessed following completion of the study intervention, an expected average of 24 weeks
|
Differences in mean change on the RFS from baseline assessment to 24 week assessment.
Items are rated on a 1 to 7 scale.
In the present analysis, we summed ratings of Family Network Relationships and Immediate Social Network Relationships as our measure of role functioning.
Scores can range from 2-14.
Higher scores mean a better outcome.
|
Participants will be assessed following completion of the study intervention, an expected average of 24 weeks
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Melanie E Bennett, Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- D1293-R
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .